Engineered drug-loaded cells and cell derivatives as a delivery platform for cancer immunotherapy
Authors:
- 2 November 2020
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 9 (4) , 1104-1116
Abstract
Recent advances in improving cancer immunotherapy have been summarized with a focus on using functionalized intact cells and cell derivatives.Keywords
Funding Information
- National Natural Science Foundation of China (21875135)
- Recruitment Program of Global Experts (D1410022)
- Shanghai Municipal Education Commission (20181704)
This publication has 74 references indexed in Scilit:
- Molecular mechanisms of cancer development in obesityNature Reviews Cancer, 2011
- Mechanisms of Dendritic Cell Trafficking Across the Blood–brain BarrierJournal of Neuroimmune Pharmacology, 2011
- Bio-inspired, bioengineered and biomimetic drug delivery carriersNature Reviews Drug Discovery, 2011
- Tumor-Associated Neutrophils: New Targets for Cancer TherapyCancer Research, 2011
- The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activityGene Therapy, 2011
- Blood–brain barrier breakdown as a therapeutic target in traumatic brain injuryNature Reviews Neurology, 2010
- In situ targeting of dendritic cells by antigen-loaded red blood cells: A novel approach to cancer immunotherapyVaccine, 2010
- Sequence Variants at 22q13 Are Associated with Prostate Cancer RiskCancer Research, 2008
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- The Immunological Synapse of CTL Contains a Secretory Domain and Membrane BridgesImmunity, 2001